Ingeniería de la célula madre

Autores/as

  • Oscar Porras Madrigal Caja Costarricense del Seguro Social, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera"

DOI:

https://doi.org/10.51481/amc.v47i2.181

Palabras clave:

Célula madre, Stem cell, hematopoyesis, trasplante de células hematopoyéticas, sangre de cordón umbilical, clonación, transferencia de núcleos, clonación terapéutica, clonación reproductiva, plasticidad

Resumen

La ingeniería de la célula madre (CM) es una tecnología aplicable en la solución de problemas de salud del ser humano relacionados con la reconstrucción de tejidos y la restauración de la función celular normal en enfermedades metabólicas, hematológica, inmunológicas y degenerativas. La investigación en la biología de la CM ha permitido definirle una identidad y establecer un grupo de células de diferente origen que comparten las características de autorrenovación y plasticidad. Este grupo incluye células embrionarias, mesenquimatosas, hematopoyéticas, umbilicales y residentes en tejidos como las CM neuronales. La investigación sobre todo con células embrionarias y los procedimientos de clonación reproductiva y trasplante de núcleos han generado un debate ético, político y religioso, en el cual solamente podemos establecer nuestra opinión si conocemos los conceptos básicos de la biología e ingeniería de las células madre.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Rosenthal N. Prometheus ́s vulture and the stem-cell promise. N EnglJ Med 2003; 349:267-274.

Garrido Colino C. Estado actual de la investigación con célulasmadre. An Pediatr (Barc) 2003; 59:552-558.

Sylvester KG, Longaker MT. Stem cells: review and update. ArchSurg 2004; 139:93-99.

Blau HM, Brazelton TR, Weimann JM. The evolving concept of astem cell: entity or function? Cell 2001; 105:829-841.

van der Kooy D, Weiss S. Why stem cells? Science 2000; 287:1439-

Evans MJ, Kaufman MH. Establishment in culture of pluripotentialstem from mouse embryos. Nature 1981; 292:154-156.

Bradley A, Evans M, Kaufman MH, Robertson E. Formation ofgerm-like chimaeras from embryo-derived teratocarcinoma cell lines.Nature 1984; 309:255-256.

Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, SwiergielJJ, Marshall VS, et al. Embryonic stem cell lines derived from humanblastocysts. Science 1998; 282:1145-1147.

Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KH. Viableoffspring derived from fetal and adult mammalian cells. Nature 1997;385:810-813.

Hochedlinger K, Jaenisch R. Nuclear transplantation, embryonicstem cells, and the potential for cell therapy. N Engl J Med 2003;349:275-286.

Lisker R. Ethical and legal issues in therapeutic cloning and the studyof stem cells. Arch Med Res 2003; 34:607–611.

Rideout WMIII, Hochedlinger K, Kyba M Daley GO Jaenisch.Correction of a genetic defect by nuclear transplantation and com-bined cell and gene therapy. Cell 2002; 109:17-27.

Gurdon JB, Byrne JA, Simonsson S. Nuclear reprogramming andstem cell creation. Proc Natl Acad Sci USA 2003; 100:11819-11822.

Selkirk SM. Gene therapy in clinical medicine. Postgrad Med J 2004;80:560-570.

Cavazzana-Calvo M, Hacein-Bey-Abina S, de Saint BG, Gross F,Yvon E, Nusbaum P, et al. Gene therapy of human severe combinedimmunodeficiency (SCID)-X1 disease. Science 2000; 288:669-672.

Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, deVillartay JP, et al. Sustained correction of X-linked severe combinedimmunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185-1193.

Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A, et al.Correction of ADA-SCID by stem cell gene therapy combined withnonmyeloablative conditioning. Science 2002; 296:2410-2413

Nathwani AC, Davidoff AM, Linch DC. A review of gene therapy forhaematological disorders. Br. J Haematol 2005; 128:3-17.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP,Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell prolif-eration in two patients after gene therapy for SCID-X1. Science 2003;302:415-419.

Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, WulffraatN, McIntyre E, et al. A serious adverse event after successful genetherapy for X-linked severe combined immunodeficiency. N Engl JMed 2003; 348: 255-256.

McCormack MP, Rabbitts TH. Activation of the T-cell oncogeneLMO2 after gene therapy for X-linked severe combined immunode-ficiency. N Engl J Med 2004; 350:913-922.

Horwitz EM. Stem cell plasticity: the growing potential of cellulartherapy. Arch Med Res 2003; 34:600-606.

Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S,Gardner R, et al. Multi-organ, multi-lineage engraftment by a singlebone marrow-derived stem cell. Cell 2001; 105:369-377.

Wurmser AE, Gage FH. Stem cells: cell fusion causes confusion.Nature 2002; 416:485-487.

Terada N, Hamazaki T, Oka M, Hoki M, Mastalerz DM, Nakano Y, etal. Bone marrow cells adopt the phenotype of other cells by sponta-neous cell fusion. Nature 2002; 416:542-545.

Ying QIL, Nichols J, Evans EP, Smith AG. Changing potency byspontaneous fusion. Nature 2002; 416:545-548.

Szilvassy SJ. The biology of hematopoietic stem cells. Arch Med Res2003; 34:446-460.

Baron F, Storb R, Little MT. Hematopoietic cell transplantation: fivedecades of progress. Arch Med Res 2003; 34:528-544.

Mayani H, Lansdorp PM. Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells. Stem Cells 1998;16:153-165.

Wognum AW, Eaves AC, Thomas TE. Identification and isolation ofhematopoietic stem cells. Arch Med Res 2003; 34:461-475.

Cohen Y, Nagler A. Cord blood biology and transplantation. IMAJ2004; 6:39-46.

Mayani H, Alvarado-Moreno JA, Flores-GuzmanP. Biology ofhuman hematopoietic stem and progenitor cells present in circulation.Arch Med Res 2003; 34:476-488.

Summer R, Kotton DN, Liang S, Fitzsimmons K, Sun X, Fine A.Embryonic lung side population cells are hematopoietic and vascularprecursors. Am J Respir Cell Mol Biol 2005; (en prensa).

Hwang WS, Ryu YJ, Park JH, Park ES, Lee EG, Koo JM, et al.Evidence of a pluripotent human embryonic stem cell line derivedfrom a cloned blastocyst. Science 2004; 303:1669-1674.

Cowan CA, Klimanskaya I, McMahon J, Atienza J, Witmyer J,Zucker JP, et al. Derivation of embryonic stem-cell lines from humanblastocysts. N Engl J Med 2004; 350:1353-1356.

Phimister EG, Drazen JM. Two fillips for human embryonic stemcells. N Engl J Med 2004; 350:1351-1352.

Tuch BE, Scott H, Armati PJ, Tabiin MT, Wang LP. Use of humanfetal tissue for biomedical research in Australia, 1994-2002. Med JAust 2003; 179:547-550.74

Landry DW, Zucker HA. Embryonic death and the creation of humanembryonic stem cells. J Clin Invest 2004; 114:1184-1186.

Sandel MJ. Embryo ethics – The moral logic of stem-cell research. NEngl J Med 2004; 351:207-209.

McHugh PR. Zygote and “clonote” – The ethical use of embryonicstem cells. N Engl J Med 2004; 351:209-211.

Kiessling AA. Eggs alone. Human parthenotes: an ethical source ofstem cells for therapies? Nature 2005; 434:145.

Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM.Contribution of transplanted bone marrow cells to Purkinje neuronsin human adult brains. Proc Natl Acad Sci USA 2003; 100:2088-2093.

Quaini F, Urbanek K, Beltrami AP, Finato N, Beltami CA, Nadal-Ginard B, et al. Chimerism of the transplanted heart. N Engl J Med2002; 346:5-15.

Gluckman E, Rocha V, Chastang C, Eurocord-Cord Blood TransplantGroup. Cord blood hamtopoietic stem cells biology and transplanta-tion. Hematology 1998; 1:1-14.

Sirchia G, Rebulla P. Placental/umbilical cord blood transplantation.Haematologica 1999; 84:738-747.

Lewis ID. Clinical and experimental uses of umbilical cord blood. IntMed J 2002; 32:601-609.

Rocha V, Sanz G, Gluckman E, Eurocord and European blood andmarrow transplant group. Umbilical cord blood transplantation. CurrOpin Hematol 2004; 11:375-385.

Gluckman E. Ex vivo expansion of cord blood cells. Exp Hematol2004; 32:410-412.

Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al.Mesenchymal stem cell in the Wharton ́s jelly of the human umbili-cal cord. Stem Cells 2004; 22:1330-1337.

Arai S, Klingemann HG. Hematopoietic stem cell transplantation:bone marrow vs. mobilized peripheral blood. Arch Med Res 2003;34:545-553.

Daley GQ, Goodell MA, Snyder EY. Realistic prospect for stem celltherapeutics. Hematology 2003; 1:398-418.

Stocum DL. Stem cells in CNS and cardiac regeneration. AdvBiochem Eng Biotechnol 2005; 93:135-159.

Gerritsen EJA, Vossen JM, Fasth A. Friedrich W, Morgan G, PorrasO. Bone marrow transplantation for autosomal recessive osteopetro-sis. A report from the Working Party on Inborn Errors of the EuropeanBone Marrow Transplantation Group. J Pediatr 1994; 125:896-902.

Porras O. Trasplante de Médula Osea.. Rev Méd Hosp Nal NiñosCosta Rica 1993; 26-28(NE):55-76.

Weissman IL. Translating stem and progenitor cell biology to theclinic: barriers and opportunities. Science 2000; 287:1442-1446.

Chao NJ, Emerson SG, Weinberg KI. Stem cell transplantation (cordblood transplants). Hematology 2004; 1:354-371.

Benito AI, Diaz MA, González-Vicent M, Sevilla J, Madero L.Hematopoietic stem cell transplantation using umbilical cord bloodprogenitors: review of current clinical results. Bone Marrow Transp2004; 33:675-690.

Barker JN, Wagner JE. Umbilical-cord blood transplantation for thetreatment of cancer. Nature 2003; 3:526-532.

Burgio GR, Gluckman E, Locatelli F. Ethical reappraisal of 15 yearsof cord-blood transplantation. Lancet 2003; 361:250-252.

Davey S, Armitage S, Rocha V, Garnier F, Brown J, Brown CJ, et al.The London Cord Blood Bank: analysis of banking and transplanta-tion outcome. Br J Haematol 2004; 125:358-365.

Gluckman E, Eurocord Netcord Organization. Ethical and legalaspects of placental/cord blood banking and transplant. Hematol J2000; 1:67-69.

Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, StornaiuoloA, Cossu G, et al. Muscle regeneration by bone marrow-derived myo-genic progenitors. Science 1998; 279:1528-1530.

Ferrari G, Mavilio F. Myogenic stem cells from the bone marrow: atherapeutic alternative for muscular distrophy? Neuromuscul Disord2002; 12 (S1):7-10.

Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow tobrain: expression of neuronal phenotypes in adult mice. Science2000; 290:1775-1779.

Petersen BE, Bowen WC, Patrene KD, Mars WM, Sullivan AK,Murase N, et al. Bone marrow as a potential source of hepatic ovalcells. Science 1999; 284:1168-1170.

Theise ND, Badve S, Saxena R, Henegariu O, Sell S, Crawford JM,et al. Derivation of hepatocytes from bone marrow cells in mice afterirradiation-induced myeloablation. Hepatology 2000; 31:235-240.

Lumelsky N, Blondel O, Laeng P, Velasco I, Ravin R, McKay R.Differentiation of embryonic stem cells to insulin-secreting structuressimilar to pancreatic islets. Science 2001; 292:1389-1394.

Smits AM, van Vliet P, Hassink RJ, Goumans MJ, Doevendans PA.The role of stem cells in cardiac regeneration. J Cell Mol Med 2005;9:25-36.

Yoon YS, Lee N, Scadova H. Myocardial regeneration with bone-marrow-derived stem cells. Biol Cell 2005; 97:253-263.

Kumar D, Kamp TJ, Lewinter MM. Embryonic stem cells: differen-tiation into cardiomyocytes and potential for heart repair and regen-eration. Coron Artery Dis 2005; 16:111-116.

Jain M, Pfister O, Hajjar RJ, Liao R. Mesenchymal stem cells in theinfarcted heart. Coron Artery Dis 2005; 16:93-97.

Pandur P. What does it take to make a heart? Biol Cell 2005; 97:197-210.

Wollert KC, Drexler H. Clinical applications of stem cells for theheart. Circ Res 2005; 96:151-163.

Menasche P. Skeletal myoblast for cell therapy. Coron Artery Dis2005; 16:105-110.75.Kh Haider H, Ashraf M. Bone marrow stem cells in the infarctedheart. Coron Artery Dis 2005; 16:99-103

Descargas

Publicado

2005-04-01

Cómo citar

Porras Madrigal, O. (2005). Ingeniería de la célula madre. Acta Médica Costarricense, 47(2), 69–75. https://doi.org/10.51481/amc.v47i2.181

Artículos más leídos del mismo autor/a

1 2 > >>